Navigation Links
Cancer drug shortages mean higher costs and greater risk for patients
Date:3/21/2013

A national survey of health professionals showed that drug shortages are taking a heavy toll on cancer patients, forcing treatment changes and delays that for some patients meant worse outcomes, more therapy-related complications and higher costs. St. Jude Children's Research Hospital investigators played an important role in the study.

The survey queried oncology pharmacists and others involved in managing cancer drug shortages for academic medical centers, community hospitals and other cancer treatment facilities nationwide. Of the 243 individuals who completed the survey, 98 percent reported having dealt with a shortage of at least one chemotherapy agent or other essential cancer-related drug in the previous 12 months. Ninety-three percent reported that shortages forced delays in chemotherapy administration or other changes in cancer drug therapy.

Researchers found the shortages also disrupted cancer research and added to the cost and risks associated with cancer treatment. One institution linked a patient's death to a shortage-related medication mistake. Overall, 16 percent of respondents tied shortages to adverse patient outcomes, including disease progression or more treatment-related complications.

The survey is the first to focus specifically on the impact of cancer-related drug shortages. It was conducted by the Hematology/Oncology Pharmacy Association and focused on a 12-month period ending in October 2011. The results appear in the April 1 edition of the American Journal of Health-System Pharmacy.

"This survey documents the risk that drug shortages pose to cancer patients of all ages,"said the study's senior author, James Hoffman, Pharm.D., an associate member of the St. Jude Department of Pharmaceutical Sciences and the hospital's medication outcomes and safety officer. "To cure cancer patients we must often use complex treatment regimens, and shortages add unnecessary complexity. Unlike medications for other diseases, there are few, if any, therapeutically equivalent alternatives available for many oncology drugs in short supply.

"Drug supplies remain unpredictable and serious problems persist," Hoffman said. In February, the University of Utah Drug Information Service was tracking national and regional shortages of more than 320 drugs, which is the highest number since 2010. The University of Utah Drug Information Service tracks drug shortages and provides advice about managing shortages through the American Society of Health-System Pharmacists.

The survey follows an earlier St. Jude-led study that linked a shortage of the chemotherapy drug mechlorethamine to a greater risk of relapse for some young Hodgkin lymphoma patients. Relapse meant those patients underwent additional intensive therapy that left them at greater risk for infertility and other treatment-related health problems later.

Multiple factors contribute to drug shortages, including manufacturing and quality problems, production delays and discontinuations. Earlier studies have shown that most shortages occur in the supply chain of generic injectable drugs, particularly medications to combat cancer and infections. In 2012, new federal legislation gave the U.S. Food and Drug Administration additional tools to prevent and ease drug shortages, including requiring manufacturers to report anticipated supply problems of key medications. "While the FDA and others have worked diligently to address the problem, additional action is needed to address continuing shortages," Hoffman said.

The survey found shortages increase health care costs as scarcity drives up the price and requires staff time to manage the problem. About one-third of institutions in this survey reported pharmacy staff spent at least 20 hours each week working on issues related to the drug shortage. That included time spent trying to find scarce medications to purchase or identify alternatives. Eighty-five percent of respondents reported shortages led to higher medical costs.

Drug shortages also disrupted the clinical trials that are essential for developing new cancer treatments. This survey found that shortages forced 44 percent of institutions to either halt or delay enrollment in clinical trials. The problem also led some providers to change or omit medications.

In this survey, the drugs most frequently reported as being in short supply were fluorouracil, leucovorin, liposomal doxorubicin and paclitaxel. Such shortages hit patients battling ovarian, breast and colorectal cancers particularly hard. For some patients, the survey found shortages meant traveling to other institutions for treatment or receiving alternative medications. For other patients, it meant treatment was delayed or continued with either lower doses of the missing drugs or without the drugs at all.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Genetic risk strategies needed for young, black, female breast cancer patients, Moffitt study shows
2. Lung Cancer Asbestos Victims Center Now Urges Families To Help Them Identify A Nonsmoker Loved One Who Had Exposure To Asbestos In The Workplace And Now Has Lung Cancer
3. Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
4. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
5. Minimally Invasive Surgery for Treatment of Colorectal Cancer Yields Optimal Outcomes for Patients
6. New imaging agent enables better cancer detection, more accurate staging
7. BIDMC investigator James Mier, M.D., awarded prominent grant for kidney cancer research
8. Toxicity map of brain may help protect cognition for cancer patients
9. Lung Cancer Asbestos Victims Center Now Urges All Industrial Workers Who Had Exposure to Asbestos at Work and Now Have Lung Cancer to Call Them About Possible Compensation
10. Highlights from the March GIE: Gastrointestinal Endoscopy special issue on colorectal cancer
11. University of Maryland researchers identify fish protein that may inhibit cancer metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... (PRWEB) , ... August 05, 2020 , ... Today, ... , the leading trade and investment platform for Africa, announced that they have entered ... YPO Africa and Invest Africa to support each other in their African impact efforts, ...
(Date:8/3/2020)... ... August 03, 2020 , ... Evolution Labs ... Health and Prevention program district-wide, developed to help students navigate a range of ... Florida schools and districts must provide their students with preventative lessons after recent ...
(Date:7/31/2020)... ... July 31, 2020 , ... ... Clinical Research’s internal medicine site in Savannah, GA. Visitors included Moncef Slaoui, ... In May, the federal government announced the OWS program to accelerate the development, ...
(Date:7/22/2020)... ... ... Whatever we call them – sunspots, age spots, liver spots, or solar ... Seelal, a Certified Registered Physician Assistant specializing in Dermatology with Advanced Dermatology PC ... us look older.” , In terms of the name, ‘sunspots’ or the medical term ...
(Date:7/22/2020)... BREA, Calif. (PRWEB) , ... ... ... Healthcare announces additional investment to reduce the risks of infectious diseases for ... implementing leading-edge disinfectant technologies, and expanding the infection prevention resources. This timely ...
Breaking Medicine News(10 mins):
(Date:8/5/2020)... ... August 04, 2020 , ... ... therapy services vital to their health and quality of life unless Congress and ... American Speech-Language-Hearing Association (ASHA) warns today. , At issue is ...
(Date:8/3/2020)... ATLANTA (PRWEB) , ... August 03, 2020 , ... ... Business Continuity Emergency Operations Planning services for small business owners. ... be unable to manage or communicate with their teams for 30-90 days as ...
(Date:7/31/2020)... , ... July 31, 2020 , ... ... clearance for reprocessing the St. Jude Medical BRK Transseptal Needle and the Baylis ... is a milestone in single-use device reprocessing, as no other company is able ...
Breaking Medicine Technology: